Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors

Next Previous
Trial Profile

An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nadunolimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Male breast cancer; Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms CANFOUR
  • Sponsors Cantargia

Most Recent Events

  • 22 Aug 2024 Status changed from active, no longer recruiting to completed.
  • 20 Jun 2024 According to a Cantargia AB media release, data from this trial will be presented at ESMO Gastrointestinal Cancer Congress 2024 in Munich June 26-29.
  • 20 Jun 2024 Results (n=73) presented in the Cantargia Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top